CD117阴性胃肠道间质瘤的分析
Analysis of CD117-negative gastrointestinal stromal tumors.
作者信息
Tzen Chin-Yuan, Mau Bey-Liing
机构信息
Department of Pathology, Mackay Memorial Hospital, 45, Minsheng Road, Tamshui, Taipei, Taiwan, China.
出版信息
World J Gastroenterol. 2005 Feb 21;11(7):1052-5. doi: 10.3748/wjg.v11.i7.1052.
AIM
To identify the gastrointestinal stromal tumors (GISTs) that are negative for CD117 expression by immunohistochemistry and to characterize their malignant potential.
METHODS
A total of 108 primary mesenchymal tumors of the gastrointestinal tract were screened to select CD117-negative tumors, from which KIT (exons 9, 11, 13, and 17) and PDGFRA (exons 10, 12, 14, and 18) were sequenced to identify GISTs. Tumor recurrence and distant metastasis were used as the criteria of malignancy.
RESULTS
The result showed that approximately 25% (29/108) of the gastrointestinal mesenchymal tumors were negative for CD117 and approximately 6% (7/108) of the tumors were CD117-negative GISTs. All these CD117-negative tumors had a mutated KIT and a wild-type PDGFRA. All CD117-negative GISTs with mutations at codons 557/558 of KIT had mitotic counts >10/50 high power field, and 75% (3/4) of them showed multiple recurrence or distant metastasis.
CONCLUSION
CD117-negative KIT mutated GISTs account for approximately 6% of the gastrointestinal mesenchymal tumors. Tumor recurrence or distant metastasis correlates to both the KIT mutations at codons 557/558 and the mitotic counts, but not to the tumor size.
目的
鉴定免疫组化检测CD117表达阴性的胃肠道间质瘤（GIST），并明确其恶性潜能。
方法
对108例原发性胃肠道间叶肿瘤进行筛查，以选择CD117阴性肿瘤，对其进行KIT（第9、11、13和17外显子）和PDGFRA（第10、12、14和18外显子）测序以鉴定GIST。以肿瘤复发和远处转移作为恶性标准。
结果
结果显示，约25%（29/108）的胃肠道间叶肿瘤CD117阴性，约6%（7/108）的肿瘤为CD117阴性GIST。所有这些CD117阴性肿瘤均有KIT突变和野生型PDGFRA。所有KIT第557/558密码子发生突变的CD117阴性GIST，其有丝分裂计数>10/50高倍视野，其中75%（3/4）出现多次复发或远处转移。
结论
CD117阴性KIT突变型GIST约占胃肠道间叶肿瘤的6%。肿瘤复发或远处转移与KIT第557/558密码子突变及有丝分裂计数相关，但与肿瘤大小无关。
Zotero 插件